Robert Lowsky

BMT specialist, Hematologist

Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center

Blood and Marrow Transplant Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-723-0822
Learn More About the Clinic Getting Here Make An Appointment

Hematology Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Fellowship: Toronto General Hospital (1993) Canada

Internship: Toronto General Hospital (1989) Canada

Residency: Toronto General Hospital (1991) Canada

Board Certification: Internal Medicine, Royal College of Physicians and Surgeons (1992)

Medical Education: McGill University (1988) Canada

FRCP, Coll of Physicians/Surgs Canada, Hematology (1993)

FRCP, Coll of Physicians/Surgs Canada, Internal Medicine (1991)

MD, McGill University, Medicine (1988)

Administrative Appointments

Director, BMT Fellowship Program, Blood and Marrow Transplantation, Stanford University (2002 - Present)

Director, Apheresis Unit, Blood and Marrow Transplantation, Stanford University (2005 - Present)

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms
Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., & Lowsky, R. (2014). Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20(6), 837-843.

Identification of gene microarray expression profiles in patients with chronic graft-versus-host disease following allogeneic hematopoietic cell transplantation
Kohrt, H. E., Tian, L., Li, L., Alizadeh, A. A., Hsieh, S., & Lowsky, R. (2013). Identification of gene microarray expression profiles in patients with chronic graft-versus-host disease following allogeneic hematopoietic cell transplantation. CLINICAL IMMUNOLOGY, 148(1), 124-135.

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence
Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., & Miklos, D. B. (2012). Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. BLOOD, 119(25), 6145-6154.

Rare cells predict GVHD.
Strober, S., & Lowsky, R. (2012). Rare cells predict GVHD. Blood, 119(21), 4820-4821.

Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants
Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Sarwal, M., & Strober, S. (2012). Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants. AMERICAN JOURNAL OF TRANSPLANTATION, 12(5), 1133-1145.

Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma
Chen, A. I., Negrin, R. S., McMillan, A., Shizuru, J. A., JOHNSTON, L. J., & Stockerl-Goldstein, K. (2012). Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. BONE MARROW TRANSPLANTATION, 47(4), 516-521.

Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation
Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., & Negrin, R. (2012). Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. BONE MARROW TRANSPLANTATION, 47(4), 581-588.

Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation.
Kohrt, H. E., Müller, A., Baker, J., Goldstein, M. J., Newell, E., & Strober, S. (2011). Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation. Blood, 118(19), 5319-5329.

Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., & Negrin, R. S. (2011). Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1679-1687.

Translational studies in hematopoietic cell transplantation: Treatment of hematologic malignancies as a stepping stone to tolerance induction
Strober, S., Spitzer, T. R., Lowsky, R., & Sykes, M. (2011). Translational studies in hematopoietic cell transplantation: Treatment of hematologic malignancies as a stepping stone to tolerance induction. SEMINARS IN IMMUNOLOGY, 23(4), 273-281.

Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY
Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., & Johnston, L. (2011). Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. BONE MARROW TRANSPLANTATION, 46(2), 192-199.

Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia
Jones, C. D., Arai, S., Lowsky, R., Tyan, D. B., Zehnder, J. L., & Miklos, D. B. (2010). Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 150(5), 637-639.

Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma
Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., & Horning, S. J. (2010). Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16(8), 1145-1154.

NKT cells, Treg, and their interactions in bone marrow transplantation
Kohrt, H. E., Pillai, A. B., Lowsky, R., & Strober, S. (2010). NKT cells, Treg, and their interactions in bone marrow transplantation. EUROPEAN JOURNAL OF IMMUNOLOGY, 40(7), 1862-1869.

Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure
Benjamin, J. E., Chen, G. L., Cao, T. M., Cao, P. D., Wong, R. M., & Laport, G. G. (2010). Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. BONE MARROW TRANSPLANTATION, 45(2), 303-309.

Nonmyeloablative conditioning with total lymphoid irradiation and antithymocyte globulin: an update
Kohrt, H., & Lowsky, R. (2009). Nonmyeloablative conditioning with total lymphoid irradiation and antithymocyte globulin: an update. CURRENT OPINION IN HEMATOLOGY, 16(6), 460-465.

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., & Lowsky, R. (2009). TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 114(5), 1099-1109.

Total lymphoid irradiation for graft-versus-host disease protection.
Kohrt, H., & Lowsky, R. (2009). Total lymphoid irradiation for graft-versus-host disease protection. Current opinion in oncology, 21, S23-6.

Brief report: Tolerance and chimerism after renal and hematopoietic-cell transplantation
Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Millan, M. T., & Strober, S. (2008). Brief report: Tolerance and chimerism after renal and hematopoietic-cell transplantation. NEW ENGLAND JOURNAL OF MEDICINE, 358(4), 362-368.

Thymoglobulin and regulatory T cells in organ and hematopoietic cell transplantation
Lowsky, R. (2007). Thymoglobulin and regulatory T cells in organ and hematopoietic cell transplantation. TRANSPLANTATION, 84(11), S20-S26.

RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell lines
Pastural, E., Takahashi, N., Dong, W.-F., Bainbridge, M., Hull, A., & Geyer, C. R. (2007). RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell lines. ONCOGENE, 26(11), 1586-1594.

High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma
Law, L. Y., Horning, S. J., Wong, R. M., Johnston, L. J., Laport, G. G., & Stockerl-Goldstein, K. E. (2006). High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12(7), 703-711.

Total lymphoid irradiation and transplantation tolerance
Lowsky, R., & Negrin, R. S. (2006). Total lymphoid irradiation and transplantation tolerance. CURRENT OPINION IN ORGAN TRANSPLANTATION, 11(1), 54-61.

Protective conditioning for acute graft-versus-host disease
Lowsky, R., Takahashi, T., Liu, Y. P., Dejbakhsh-Jones, S., GRUMET, F. C., & Strober, S. (2005). Protective conditioning for acute graft-versus-host disease. NEW ENGLAND JOURNAL OF MEDICINE, 353(13), 1321-1331.

A technique of bone marrow collection from vertebral bodies of cynomolgus macaques for transplant studies
Flores, M. G., Holm, B., Larson, M. J., Lau, M. K., Si, M. S., & Borie, D. C. (2005). A technique of bone marrow collection from vertebral bodies of cynomolgus macaques for transplant studies. JOURNAL OF SURGICAL RESEARCH, 124(2), 280-288.

Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose
Cao, T. M., Shizuru, J. A., Wong, R. M., Sheehan, K., Laport, G. G., & Lowsky, R. (2005). Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose. BLOOD, 105(6), 2300-2306.

CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies
Cao, T. M., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., & Lowsky, R. (2005). CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. EXPERIMENTAL HEMATOLOGY, 33(3), 279-285.

Short tandem repeat analysis to monitor chimerism in Macaca fascicularis
Lau, M., Vayntrub, T., GRUMET, F. C., Lowsky, R., Strober, S., & Borie, D. (2004). Short tandem repeat analysis to monitor chimerism in Macaca fascicularis. AMERICAN JOURNAL OF TRANSPLANTATION, 4(9), 1543-1548.

Approaches to transplantation tolerance in humans
Strober, S., Lowsky, R. J., Shizuru, J. A., Scandling, J. D., & Millan, M. T. (2004). Approaches to transplantation tolerance in humans. TRANSPLANTATION, 77(6), 932-936.

Bronchiolitis obliterans organizing pneumonia in a patient with chronic myelogenous leukemia developing after initiation of interferon and cytosine arabinoside
Patel, M., Ezzat, W., Pauw, K. L., & Lowsky, R. (2001). Bronchiolitis obliterans organizing pneumonia in a patient with chronic myelogenous leukemia developing after initiation of interferon and cytosine arabinoside. EUROPEAN JOURNAL OF HAEMATOLOGY, 67(5-6), 318-321.